Search

Your search keyword '"Masi G."' showing total 1,276 results
Start Over Author "Masi G." Language english
1,276 results on '"Masi G."'

1. Vine performance of ‘Italia' table grape in relation to organic soil amendment

Author

Tarricone L., Masi G., Roccotelli S., Caputo A.R., and Crupi P.

Subjects
Microbiology, QR1-502, Physiology, QP1-981, Zoology, QL1-991
Abstract

The following research took place during the 2018 − ‘19 season in ‘Italia' table grape vineyard in Apulia. Four treatments were compared: no fertilized (T), organic amendment fertilized (B) at rate of 5.0 ton/hectare, equivalent at the rate of 100 Kg N ha−1, 75 Kg P2O5 ha−1 and 75 Kg K202 ha−1; mineral fertilized (M) at the same rate of N, P2O5 and K2O of organic fertilized vines and finally a cover crops treatment with a mixture of vetch, pea and lentil (S). Leaf gas exchange during summer season shown significant differences in term of net CO2 assimilation, stomatal conductance, transpiration onto organic fertilized vines respect to control vines. Vines fertilized with organic amendment shown a better water status during warmest summer days since organic compounds improve the soil-water holding capacity. Compared to unfertilized vines, vines fertilized with organic amendment have shown a significant increase in yield per vine (+ 32%) in relation to the highest cluster weight and the highest sugar content respect to mineral fertilized vines. Our results indicates that application of an high level of soil organic amendment on ‘Italia' table grape vines increase grapevines yield, berry solid soluble solid and have improved soil properties, contrasting summer drought effect.

Published
2019
Full Text
View/download PDF

2. New autochthonous vines of Campania under evaluation for inclusion in productive sector

Author

Caputo A.R., Alba V., Bergamini C., Gasparro M., Masi G., Tarricone L., Crupi P., Roccotelli S., Pepe R., and Del Lungo S.

Subjects
Microbiology, QR1-502, Physiology, QP1-981, Zoology, QL1-991
Abstract

The drastic reduction of agrobiodiversity has induced all countries in the world to implement numerous initiatives to safeguard genetic resources. The biodiversity issue is also one of the priority objectives of the global action plan for the conservation and sustainable use of FAO's cytogenetic resources and of the International Treaty on Plant Genetic Resources for Food and Agriculture. In Italy, the primary competence on genetic resources of agricultural interest is entrusted to the Ministry of Agricultural. In 2004, the Ministry entrusted the coordination of the RGV/FAO Project to CREA. The main objectives of the project, in addition to the inventory of accessions present in the collections of the structures involved, are their morphological, agronomic and molecular characterization and the productive enhancement with particular reference to the autochthonous varieties at risk of extinction. The project in question includes the activities of recovery and characterization of the viticultural germplasm illustrated in the present work. The 12 vines described here, like others yet to be rediscovered, are strongly linked to small winegrowers and indissolubly characterial of a territory in Campania Region that from the socio-cultural (rather fragmented agricultural system) and environmental orography point of view, like the national one, is very diversified.

Published
2019
Full Text
View/download PDF

4. Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience

Author

Moretto, R., Germani, M.M., Borelli, B., Conca, V., Rossini, D., Boraschi, P., Donati, F., Urbani, L., Lonardi, S., Bergamo, F., Cerma, K., Ramondo, G., D’Amico, F.E., Salvatore, L., Valente, G., Barbaro, B., Giuliante, F., Di Maio, M., Masi, G., and Cremolini, C.

Published
2024
Full Text
View/download PDF

7. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Author

Rimini, M., Rimassa, L., Ueshima, K., Burgio, V., Shigeo, S., Tada, T., Suda, G., Yoo, C., Cheon, J., Pinato, D.J., Lonardi, S., Scartozzi, M., Iavarone, M., Di Costanzo, G.G., Marra, F., Soldà, C., Tamburini, E., Piscaglia, F., Masi, G., Cabibbo, G., Foschi, F.G., Silletta, M., Pressiani, T., Nishida, N., Iwamoto, H., Sakamoto, N., Ryoo, B.-Y., Chon, H.J., Claudia, F., Niizeki, T., Sho, T., Kang, B., D’Alessio, A., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., Tsuji, K., Ishikawa, T., Tajiri, K., Ochi, H., Yasuda, S., Toyoda, H., Ogawa, C., Nishimur, T., Hatanaka, T., Kakizaki, S., Shimada, N., Kawata, K., Tanaka, T., Ohama, H., Nouso, K., Morishita, A., Tsutsui, A., Nagano, T., Itokawa, N., Okubo, T., Arai, T., Imai, M., Naganuma, A., Koizumi, Y., Nakamura, S., Joko, K., Iijima, H., Hiasa, Y., Pedica, F., De Cobelli, F., Ratti, F., Aldrighetti, L., Kudo, M., Cascinu, S., and Casadei-Gardini, A.

Published
2022
Full Text
View/download PDF

8. Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials

Author

Dell’Aquila, E., Rossini, D., Fulgenzi, C.A.M., Passardi, A., Tamburini, E., Vetere, G., Carullo, M., Citarella, F., Antoniotti, C., Zaniboni, A., Pietrantonio, F., Spagnoletti, A., Marmorino, F., Borelli, B., Allegrini, G., Lonardi, S., Nappo, F., Masi, G., Cremolini, C., and Santini, D.

Published
2022
Full Text
View/download PDF

9. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib

Author

Rimini, M., Kudo, M., Tada, T., Shigeo, S., Kang, W., Suda, G., Jefremow, A., Burgio, V., Iavarone, M., Tortora, R., Marra, F., Lonardi, S., Tamburini, E., Piscaglia, F., Masi, G., Cabibbo, G., Foschi, F.G., Silletta, M., Kumada, T., Iwamoto, H., Aoki, T., Goh, M.J., Sakamoto, N., Siebler, J., Hiraoka, A., Niizeki, T., Ueshima, K., Sho, T., Atsukawa, M., Hirooka, M., Tsuji, K., Ishikawa, T., Takaguchi, K., Kariyama, K., Itobayashi, E., Tajiri, K., Shimada, N., Shibata, H., Ochi, H., Yasuda, S., Toyoda, H., Fukunishi, S., Ohama, H., Kawata, K., Tani, J., Nakamura, S., Nouso, K., Tsutsui, A., Nagano, T., Takaaki, T., Itokawa, N., Okubo, T., Arai, T., Imai, M., Joko, K., Koizumi, Y., Hiasa, Y., Cucchetti, A., Ratti, F., Aldrighetti, L., Cascinu, S., and Casadei-Gardini, A.

Published
2021
Full Text
View/download PDF

10. Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO

Author

Rossini, D., Boccaccino, A., Sbrana, A., Daniel, F., Borelli, B., Raimondi, A., Santini, D., Conca, V., Tomasello, G., Caponnetto, S., Marmorino, F., Zaniboni, A., Buonadonna, A., Masi, G., Lonardi, S., Pietrantonio, F., Falcone, A., Antonuzzo, A., and Cremolini, C.

Published
2021
Full Text
View/download PDF

11. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma

Author

Rapposelli, I.G., Shimose, S., Kumada, T., Okamura, S., Hiraoka, A., Di Costanzo, G.G., Marra, F., Tamburini, E., Forgione, A., Foschi, F.G., Silletta, M., Lonardi, S., Masi, G., Scartozzi, M., Nakano, M., Shibata, H., Kawata, K., Pellino, A., Vivaldi, C., Lai, E., Takata, A., Tajiri, K., Toyoda, H., Tortora, R., Campani, C., Viola, M.G., Piscaglia, F., Conti, F., Fulgenzi, C.A.M., Frassineti, G.L., Rizzato, M.D., Salani, F., Astara, G., Torimura, T., Atsukawa, M., Tada, T., Burgio, V., Rimini, M., Cascinu, S., and Casadei-Gardini, A.

Published
2021
Full Text
View/download PDF

14. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies

Author

Marmorino, F., Rossini, D., Lonardi, S., Moretto, R., Zucchelli, G., Aprile, G., Dell’Aquila, E., Ratti, M., Bergamo, F., Masi, G., Urbano, F., Ronzoni, M., Libertini, M., Borelli, B., Randon, G., Buonadonna, A., Allegrini, G., Pella, N., Ricci, V., Boccaccino, A., Latiano, T.P., Cordio, S., Passardi, A., Tamburini, E., Boni, L., Falcone, A., and Cremolini, C.

Published
2019
Full Text
View/download PDF

16. Diagnostics for plasma control – From ITER to DEMO

Author

Biel, W., Albanese, R., Ambrosino, R., Ariola, M., Berkel, M.V., Bolshakova, I., Brunner, K.J., Cavazzana, R., Cecconello, M., Conroy, S., Dinklage, A., Duran, I., Dux, R., Eade, T., Entler, S., Ericsson, G., Fable, E., Farina, D., Figini, L., Finotti, C., Franke, Th., Giacomelli, L., Giannone, L., Gonzalez, W., Hjalmarsson, A., Hron, M., Janky, F., Kallenbach, A., Kogoj, J., König, R., Kudlacek, O., Luis, R., Malaquias, A., Marchuk, O., Marchiori, G., Mattei, M., Maviglia, F., De Masi, G., Mazon, D., Meister, H., Meyer, K., Micheletti, D., Nowak, S., Piron, Ch., Pironti, A., Rispoli, N., Rohde, V., Sergienko, G., El Shawish, S., Siccinio, M., Silva, A., da Silva, F., Sozzi, C., Tardocchi, M., Tokar, M., Treutterer, W., and Zohm, H.

Published
2019
Full Text
View/download PDF

19. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO

Author

Dell’Aquila, E., Cremolini, C., Zeppola, T., Lonardi, S., Bergamo, F., Masi, G., Stellato, M., Marmorino, F., Schirripa, M., Urbano, F., Ronzoni, M., Tomasello, G., Zaniboni, A., Racca, P., Buonadonna, A., Allegrini, G., Fea, E., Di Donato, S., Chiara, S., Tonini, G., Tomcikova, D., Boni, L., Falcone, A., and Santini, D.

Published
2018
Full Text
View/download PDF

22. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

Author

Martini, G, Ciardiello, D, Famiglietti, V, Rossini, D, Antoniotti, C, Troiani, T, Napolitano, S, Esposito, L, Latiano, T P, Maiello, E, Del Re, M, Lonardi, S, Aprile, G, Santini, D, Masi, G, Avallone, A, Normanno, N, Pietrantonio, F, Pinto, C, Ciardiello, F, Cremolini, C, Martinelli, E, Martini, G, Ciardiello, D, Famiglietti, V, Rossini, D, Antoniotti, C, Troiani, T, Napolitano, S, Esposito, L, Latiano, T P, Maiello, E, Del Re, M, Lonardi, S, Aprile, G, Santini, D, Masi, G, Avallone, A, Normanno, N, Pietrantonio, F, Pinto, C, Ciardiello, F, Cremolini, C, and Martinelli, E

Subjects
metastatic colorectal cancer, cetuximab, rechallenge, immunotherapy
Abstract

The rechallenge strategy is based on the concept that a subset of patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor receptor (EGFR) inhibition, after progression to an anti-EGFR based-therapy. We performed a pooled analysis of two-phase II prospective trials to determine the role of rechallenge in third-line mCRC patients with RAS/BRAF WT baseline circulating tumor DNA (ctDNA). Individual data of 33 and 13 patients from CAVE and CRICKET trials that received as third-line therapy cetuximab rechallenge were collected. Overall survival (OS), Progression-free survival (PFS), Overall response rate (ORR), Stable disease (SD) > 6 months were calculated. Adverse events were reported. For the whole 46 patient population, median PFS (mPFS) was 3.9 months (95% Confidence Interval, CI 3.0-4.9) with median OS (mOS) of 16.9 months (95% CI 11.7-22.1). For CRICKET patients, mPFS was 3.9 months (95% CI 1.7-6.2); mOS was 13.1 months (95% CI 7.3-18.9) with OS rates at 12, 18, and 24 months of 62%, 23%, and 0%, respectively. For CAVE patients, mPFS was 4.1 months (95% CI 3.0-5.2); mOS was 18.6 months (95% CI 11.7-25.4) with OS rates at 12, 18, 24 months of 61%, 52%, 21%, respectively. Skin rash was more frequently reported in CAVE trial (87.9% vs. 30.8%; p = 0.001), whereas a increased incidence of hematological toxicities was observed in CRICKET trial (53.8%% vs. 12.1%; p = 0.003). Third-line cetuximab rechallenge in combination with either irinotecan or avelumab in RAS/BRAF WT ctDNA mCRC patients represents a promising therapy.

Published
2023

27. Binary asteroid population. 3. Secondary rotations and elongations

Author

Pravec, P., Scheirich, P., Kušnirák, P., Hornoch, K., Galád, A., Naidu, S.P., Pray, D.P., Világi, J., Gajdoš, Š., Kornoš, L., Krugly, Yu.N., Cooney, W.R., Gross, J., Terrell, D., Gaftonyuk, N., Pollock, J., Husárik, M., Chiorny, V., Stephens, R.D., Durkee, R., Reddy, V., Dyvig, R., Vraštil, J., Žižka, J., Mottola, S., Hellmich, S., Oey, J., Benishek, V., Kryszczyńska, A., Higgins, D., Ries, J., Marchis, F., Baek, M., Macomber, B., Inasaridze, R., Kvaratskhelia, O., Ayvazian, V., Rumyantsev, V., Masi, G., Colas, F., Lecacheux, J., Montaigut, R., Leroy, A., Brown, P., Krzeminski, Z., Molotov, I., Reichart, D., Haislip, J., and LaCluyze, A.

Published
2016
Full Text
View/download PDF

28. ASASSN-15lh: A highly super-luminous supernova

Author

Dong, Subo, Shappee, B. J., Prieto, J. L., Jha, S. W., Stanek, K. Z., Holoien, T. W.-S., Kochanek, C. S., Thompson, T. A., Morrell, N., Thompson, I. B., Basu, U., Beacom, J. F., Bersier, D., Brimacombe, J., Brown, J. S., Bufano, F., Chen, Ping, Conseil, E., Danilet, A. B., Falco, E., Grupe, D., Kiyota, S., Masi, G., Nicholls, B., E, F. Olivares, Pignata, G., Pojmanski, G., Simonian, G. V., Szczygiel, D. M., and Woźniak, P. R.

Published
2016

32. Transcriptome signatures from discordant sibling pairs reveal changes in peripheral blood immune cell composition in Autism Spectrum Disorder

Author

Filosi, Michele, Kam-Thong, Tony, Essioux, Laurent, Muglia, Pierandrea, Trabetti, Elisabetta, Spooren, Will, Müller-Myshok, Bertram, Domenici, EnricoAlibrio G, Anchisi L, Andruccioli M, Benvenuto A, Battistella PA, Boscaini F, Bravaccio C, Ceppi E, Cosentino D, Curatolo P, Da Ros L, Bernardina BD, De Giacomo A, Di Vita G, Domenici E, Elia M, Gitti F, Grittani S, Lamanna AL, Mani E, Manzi B, Margari L, Masi G, Molteni M, Muglia P, Nardocci F, Pascotto A, Parmeggiani A, Pignatti PF, Piroddi T, Prandini P, Ratti E, Rizzini P, Russo S, Scifo R, Tancredi R, Tiberti A, Trabetti E, Zoccante L, Zuddas A., Michele Filosi , Tony Kam-Thong , Laurent Essioux , Pierandrea Muglia , Elisabetta Trabetti , Will Spooren , Bertram Müller-Myshok , Italian Autism Network, Enrico Domenici, Antonia Parmeggiani, Filosi, Michele, Kam-Thong, Tony, Essioux, Laurent, Muglia, Pierandrea, Trabetti, Elisabetta, Spooren, Will, Müller-Myshok, Bertram, Domenici, Enricoalibrio, G, Anchisi, L, Andruccioli, M, Benvenuto, A, Battistella, Pa, Boscaini, F, Bravaccio, C, Ceppi, E, Cosentino, D, Curatolo, P, Da Ros, L, Bernardina, Bd, De Giacomo, A, Di Vita, G, Domenici, E, Elia, M, Gitti, F, Grittani, S, Lamanna, Al, Mani, E, Manzi, B, Margari, L, Masi, G, Molteni, M, Muglia, P, Nardocci, F, Pascotto, A, Parmeggiani, A, Pignatti, Pf, Piroddi, T, Prandini, P, Ratti, E, Rizzini, P, Russo, S, Scifo, R, Tancredi, R, Tiberti, A, Trabetti, E, Zoccante, L, and Zuddas, A.

Subjects
0301 basic medicine, Autism Spectrum Disorder, autism spectrum disorders, Biology, Molecular neuroscience, Peripheral blood mononuclear cell, Article, lcsh:RC321-571, Transcriptome, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, transcriptomic signatures, mental disorders, medicine, Humans, Allele, Sibling, Autistic Disorder, lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry, Biological Psychiatry, Genetics, Autism, genetics, neuroscience, Blood Cells, Siblings, medicine.disease, Gene expression profiling, Psychiatry and Mental health, 030104 developmental biology, Asperger syndrome, Autism spectrum disorder, Autism, 030217 neurology & neurosurgery, Biomarkers
Abstract

Notwithstanding several research efforts in the past years, robust and replicable molecular signatures for autism spectrum disorders from peripheral blood remain elusive. The available literature on blood transcriptome in ASD suggests that through accurate experimental design it is possible to extract important information on the disease pathophysiology at the peripheral level. Here we exploit the availability of a resource for molecular biomarkers in ASD, the Italian Autism Network (ITAN) collection, for the investigation of transcriptomic signatures in ASD based on a discordant sibling pair design. Whole blood samples from 75 discordant sibling pairs selected from the ITAN network where submitted to RNASeq analysis and data analyzed by complementary approaches. Overall, differences in gene expression between affected and unaffected siblings were small. In order to assess the contribution of differences in the relative proportion of blood cells between discordant siblings, we have applied two different cell deconvolution algorithms, showing that the observed molecular signatures mainly reflect changes in peripheral blood immune cell composition, in particular NK cells. The results obtained by the cell deconvolution approach are supported by the analysis performed by WGCNA. Our report describes the largest differential gene expression profiling in peripheral blood of ASD subjects and controls conducted by RNASeq. The observed signatures are consistent with the hypothesis of immune alterations in autism and an increased risk of developing autism in subjects exposed to prenatal infections or stress. Our study also points to a potential role of NMUR1, HMGB3, and PTPRN2 in ASD.

Published
2020

34. Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

Author

Martini, G., Ciardiello, D., Famiglietti, V., Rossini, D., Antoniotti, C., Troiani, T., Napolitano, S., Esposito, L., Latiano, T. P., Maiello, E., Del Re, M., Lonardi, S., Aprile, G., Santini, D., Masi, G., Avallone, A., Normanno, N., Pietrantonio, F., Pinto, C., and Ciardiello, F.

Subjects
CIRCULATING tumor DNA, COLORECTAL cancer, EPIDERMAL growth factor receptors, CETUXIMAB, METASTASIS
Abstract

The rechallenge strategy is based on the concept that a subset of patients with RAS wild‐type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor receptor (EGFR) inhibition, after progression to an anti‐EGFR based‐therapy. We performed a pooled analysis of two‐phase II prospective trials to determine the role of rechallenge in third‐line mCRC patients with RAS/BRAF WT baseline circulating tumor DNA (ctDNA). Individual data of 33 and 13 patients from CAVE and CRICKET trials that received as third‐line therapy cetuximab rechallenge were collected. Overall survival (OS), Progression‐free survival (PFS), Overall response rate (ORR), Stable disease (SD) >6 months were calculated. Adverse events were reported. For the whole 46 patient population, median PFS (mPFS) was 3.9 months (95% Confidence Interval, CI 3.0–4.9) with median OS (mOS) of 16.9 months (95% CI 11.7–22.1). For CRICKET patients, mPFS was 3.9 months (95% CI 1.7–6.2); mOS was 13.1 months (95% CI 7.3–18.9) with OS rates at 12, 18, and 24 months of 62%, 23%, and 0%, respectively. For CAVE patients, mPFS was 4.1 months (95% CI 3.0–5.2); mOS was 18.6 months (95% CI 11.7–25.4) with OS rates at 12, 18, 24 months of 61%, 52%, 21%, respectively. Skin rash was more frequently reported in CAVE trial (87.9% vs. 30.8%; p = 0.001), whereas a increased incidence of hematological toxicities was observed in CRICKET trial (53.8%% vs. 12.1%; p = 0.003). Third‐line cetuximab rechallenge in combination with either irinotecan or avelumab in RAS/BRAF WT ctDNA mCRC patients represents a promising therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. Binary asteroid population. 2. Anisotropic distribution of orbit poles of small, inner main-belt binaries

Author

Pravec, P., Scheirich, P., Vokrouhlický, D., Harris, A.W., Kušnirák, P., Hornoch, K., Pray, D.P., Higgins, D., Galád, A., Világi, J., Gajdoš, Š., Kornoš, L., Oey, J., Husárik, M., Cooney, W.R., Gross, J., Terrell, D., Durkee, R., Pollock, J., Reichart, D.E., Ivarsen, K., Haislip, J., LaCluyze, A., Krugly, Yu. N., Gaftonyuk, N., Stephens, R.D., Dyvig, R., Reddy, V., Chiorny, V., Vaduvescu, O., Longa-Peña, P., Tudorica, A., Warner, B.D., Masi, G., Brinsfield, J., Gonçalves, R., Brown, P., Krzeminski, Z., Gerashchenko, O., Shevchenko, V., Molotov, I., and Marchis, F.

Published
2012
Full Text
View/download PDF

44. Instrumental methods for professional and amateur collaborations in planetary astronomy

Author

Mousis, O., Hueso, R., Beaulieu, J.-P., Bouley, S., Carry, B., Colas, F., Klotz, A., Pellier, C., Petit, J.-M., Rousselot, P., Ali-Dib, M., Beisker, W., Birlan, M., Buil, C., Delsanti, A., Frappa, E., Hammel, H. B., Levasseur-Regourd, A. C., Orton, G. S., Sánchez-Lavega, A., Santerne, A., Tanga, P., Vaubaillon, J., Zanda, B., Baratoux, D., Böhm, T., Boudon, V., Bouquet, A., Buzzi, L., Dauvergne, J. -L., Decock, A., Delcroix, M., Drossart, P., Esseiva, N., Fischer, G., Fletcher, L. N., Foglia, S., M. Gómez-Forrellad, J., Guarro-Fló, J., Herald, D., Jehin, E., Kugel, F., Lebreton, J. -P., Lecacheux, J., Leroy, A., Maquet, L., Masi, G., Maury, A., Meyer, F., Pérez-Hoyos, S., Rajpurohit, A. S., Rinner, C., Rogers, J. H., Roques, F., Schmude, Jr., R.W., Sicardy, B., Tregon, B., Vanhuysse, M., Wesley, A., and Widemann, T.

Published
2014
Full Text
View/download PDF

45. Phantom phone signal: Why it should be of interest for psychiatry

Author

Pisano S., Masi G., Catone G., Muratori P., Milone A., Iuliano R., Rega A., Senese V. P., Santangelo P., Riccio M. P., Bravaccio C., Pisano, S., Masi, G., Catone, G., Muratori, P., Milone, A., Iuliano, R., Rega, A., Senese, V. P., Santangelo, P., Riccio, M. P., and Bravaccio, C.

Subjects
Psychiatry, Phantom ringing, Phantom vibration
Abstract

Phantom Phone Signal (PPS) refers to the false perception of a mobile phone ringing, vibrating and blinking, when in fact it did not. A recent literature about PPS is growing, parallel to an increasing interest about its possible psychopathological implications. The present review aims to synthesize the current knowledge about the phenomenon, and to present a conceptual framework that integrates PPS as a putative index of psychopathology. Furthermore, we propose possible directions for further research. The phenomenon seems highly prevalent, irrespective of age and gender, although estimates are still inconsistent. We have analysed possible factors associated to PPS, disentangling them in person-related (i.e. characteristics of individuals who experience PPS) and phone use-related factors (i.e., time spent using the phone, time of the mobile in vibrating mode, the carrying location of the device, average number of call/message in a day, etc). Literature regarding the association between PPS and mental illness is limited, as most of the samples are not clinical and too sectorial. Preliminary data suggest that anxiety/depression and stress-related problems seem to be the psychopathological background favouring the experience of PPS. Despite PPS is a common phenomenon, it usually do not seem to significantly impact the people's quality of life. However, they deserve attention, given the huge diffusion of phone mobiles, particularly in children and adolescents, as it may be an index for emotional or stress-related difficulties. Future studies are needed to better clarify its frequency and its possible impact on everyday life. Studies in clinical samples may further clarify its psychopathological implications.

Published
2021

49. Allosteric activation of T cell antigen receptor signaling by quaternary structure relaxation

Author

Lanz, A-L, Masi, G, Porciello, N, Cohnen, A, Cipria, D, Prakaash, D, Bálint, Š, Raggiaschi, R, Galgano, D, Cole, DK, Lepore, M, Dushek, O, Dustin, ML, Sansom, MSP, Kalli, AC, and Acuto, O

Subjects
chemical and pharmacologic phenomena
Abstract

The mechanism of T cell antigen receptor (TCR-CD3) signaling remains elusive. Here, we identify mutations in the transmembrane region of TCRβ or CD3ζ that augment peptide T cell antigen receptor (pMHC)-induced signaling not explicable by enhanced ligand binding, lateral diffusion, clustering, or co-receptor function. Using a biochemical assay and molecular dynamics simulation, we demonstrate that the gain-of-function mutations loosen the interaction between TCRαβ and CD3ζ. Similar to the activating mutations, pMHC binding reduces TCRαβ cohesion with CD3ζ. This event occurs prior to CD3ζ phosphorylation and at 0°C. Moreover, we demonstrate that soluble monovalent pMHC alone induces signaling and reduces TCRαβ cohesion with CD3ζ in membrane-bound or solubilised TCR-CD3. Our data provide compelling evidence that pMHC binding suffices to activate allosteric changes propagating from TCRαβ to the CD3 subunits, reconfiguring interchain transmembrane region interactions. These dynamic modifications could change the arrangement of TCR-CD3 boundary lipids to license CD3ζ phosphorylation and initiate signal propagation.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results